Last reviewed · How we verify
NCT05676957: RESCUE-HYPO
Reperfusion With Hypothermia in Acute Ischemic Stroke
NA trial testing Thermogard XP3 in Ischemic Stroke in 30 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | Liping Liu |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 March 2023 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 March 2024 |
Drugs / interventions tested
- Thermogard XP3
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Revascularization — all drugs for Revascularization →
- Endovascular Treatment — all drugs for Endovascular Treatment →
- Reperfusion Injury — all drugs for Reperfusion Injury →
Sponsor
Liping Liu
Who can join
Adults 18 to 80, any sex, with Ischemic Stroke or Revascularization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to determine the feasibility and safety of receiving intravascular hypothermia treatment for patients experiencing endovascular treatment after acute ischemic stroke(AIS) due to a large vessel occlusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05676957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thermogard XP3
Trials testing the same drug.
- NCT03804060 — REperfusion With Cooling in CerebraL Acute IscheMia II · NA · completed
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Liping Liu trials
Trials by the same sponsor.
- NCT05670873 — Transcranial Magnetic Stimulation in Disorder of Consciousness in Acute Severe Cerebrovascular Disease Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05676957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liping Liu
- Last refreshed: 11 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05676957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing